

and take no responsibility for the  
and expressly disclaim any liability  
of the contents of this announcement.

**HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

(**合康藥業集團股份有限公司**)

(**Incorporated in the People's Republic of China with limited liability**)

(**Stock Code: 9989**)

## **ADDITIONAL ANNOUNCEMENT THE COMPANY'S SHARES WILL BE NEWLY INCLUDED IN THE FTSE GLOBAL EQUITY INDEX SERIES**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group  
Company Limited (“**Company**”), together with its subsidiaries referred to as the “**Group**”) on  
to inform the shareholders and potential investors of the Company about  
the announcement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the  
shares will be newly included in the FTSE Global Equity Index Small Cap  
index, which will become effective on December 21, 2020.

### **INFORMATION ABOUT FTSE GEIS**

FTSE GEIS includes over 16,000 large, mid, small, and micro cap companies across  
developed and emerging markets globally, with a wide range of industry sectors,  
markets and market segments.

**Shareholders and potential investors of the Company should be aware of the risks  
dealing in the securities of the Company.**